Augmentin Tablets

Country: Australia

Language: English

Source: Department of Health (Therapeutic Goods Administration)

Active ingredient:

amoxicillin trihydrate, Quantity: 286.9 mg (Equivalent: amoxicillin trihydrate, Qty 250 mg); potassium clavulanate, Quantity: 149.5 mg (Equivalent: clavulanic acid, Qty 125 mg)

Available from:

Aspen Pharmacare Australia Pty Ltd

Pharmaceutical form:

Tablet, film coated

Composition:

Excipient Ingredients: colloidal anhydrous silica; sodium starch glycollate; magnesium stearate; microcrystalline cellulose; dimeticone 200; titanium dioxide; hypromellose; propylene glycol; ethylcellulose

Administration route:

Oral

Units in package:

15, 30, 3 tablets, 90(E)

Class:

Medicine Registered

Prescription type:

(S4) Prescription Only Medicine, Not scheduled. Not considered by committee

Therapeutic indications:

AUGMENTIN is indicated in the treatment of the following infections when caused by AUGMENTIN sensitive, beta-lactamase producing organisms: Skin and Skin Structure Infections, including cases caused by beta-lactamase producing S. aureus, E. coli and Klebsiella spp. (only some strains may be sensitive). Urinary Tract Infections, including cases caused by beta-lactamase producing E. coli, P. mirabilis & Klebsiella spp. Upper Respiratory Tract Infections, such as sinusitis, including cases caused by beta-lactamase producing H.influenzae and M.catarrhalis, and otitis media, especially cases caused by beta-lactamase producing H. influenzae, M. catarrhalis and S. aureus. Lower Respiratory Tract Infections, especially cases caused by beta-lactamase producing H.influenzae and M.catarrhalis. Appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to AUGMENTIN. However, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. Once these results are known, therapy should be adjusted if appropriate. The treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to AUGMENTIN should not require the addition of another antibiotic due to the amoxicillin content of AUGMENTIN.

Product summary:

Visual Identification: white, oval biconvex tablet approx 16mm in length embossed with Augmentin on one side; Container Type: Blister Pack; Container Life Time: 18 Months; Container Temperature: Store below 25 degrees Celsius

Authorization status:

Licence status A

Authorization date:

1991-08-14